Late nephrotoxicity of peptide receptor radionuclide therapy (PRRT) and impact of selected factors – A single centre cohort study

#4335

Introduction: The most common side effect of radioligand therapy is renal damage, early or late. However, limited data exist for the long-term side effects and impact of additional risk factors on renal function in patients treated with PRRT.

Aim(s): To evaluate the nephrotoxicity treatment with 90Y-DOTATATE and tandem therapy 90Y-DOTATATE+177Lu-DOTATATE in patients with neuroendocrine tumours (NETs) including the impact of selected factors that can potentiate kidney damage, as: age, 131IMIBG therapy, chemotherapy, diabetes, arterial hypertension, number of CT scans.

Materials and methods: Retrospective analysis of 115 patients with NETs treated with PRRT in 2005-2012. Assessment of renal function was carried out during isotope treatment every 2-3 weeks, after its completion every 3 months in the first year and later once a year. Renal damage was classified according to WHO toxicity criteria. The median follow-up time from the first cycle of radioisotope treatment was 6.6 years (IQR 3,18-10,22).

Conference:

Presenting Author: Sygula A

Authors: Sygula A, Kropinska A, Kotecka-Blicharz A, Gawlik T, Wycislik M,

Keywords: Neuroendocrine tumour, PRRT, nephrotoxicity, yttrium-90, lutetium-177,